Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Enliven Therapeutics, Inc.

Stifel Nicolaus analyst Dara Azar reiterated a Buy rating on Enliven Therapeutics today and set a price target of $82.00. According to TipRanks, Az...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELVN	$60.07	+0.90%	619.31K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELVN	$60.07	+0.9%	619.31K
3
4
5
6

ELVN

Get Enliven Therapeutics, Inc. Data in Excel

Get Enliven Therapeutics, Inc. Data in Excel